PHPharming Group N.V. PHAR · NASDAQ
$9.36 -2.80% (-$0.27)
- Market cap
- $681.6M
- Enterprise value
- $636.6M
- P/E
- 73.5x
- Forward P/E
- 40.8x
- PEG
- -
- P/S
- 1.9x
- P/FCF
- 21.7x
- EV/EBITDA
- 14.9x
- ROIC
- 1.9%
- Gross margin
- 86.5%
- Net margin
- 2.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -1.1x
- Beta
- 0.09
- Free float
- 98.4%
About the company
Pharming Group N.V. is a Dutch biotechnology company that specializes in the development and commercialization of innovative drugs targeting genetically determined diseases and immune disorders. The company is particularly known for its work in producing therapeutic proteins, including medications for the treatment of rare diseases. Pharming is recognized for its research in genetic therapy and recombinant biotechnology, especially concerning the production of medicinal substances aimed at improving the quality of life for patients with severe conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Fabrice Chouraqui
Employees
407
Headquarters
Leiden
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number